Compstatin Analog Dosing Regimens for Long-Lasting Complement Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for complement-mediated disorders are inadequate in providing long-lasting inhibition of complement activation, leading to insufficient therapeutic effects and potential side effects from frequent dosing.
Innovation Solution
Development of long-acting compstatin analogs with specific dosing regimens to achieve sustained complement inhibition, including formulations and administration routes tailored for conditions such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, ischemia/reperfusion injury, and chronic respiratory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If existing treatments are used for complement-mediated disorders, then complement activation can be inhibited, but the duration of inhibition is insufficient requiring frequent dosing
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of compstatin to create analogs with altered pharmacokinetic properties. Specifically, the analogs have modified amino acid sequences and structural features that increase their half-life in circulation, enabling sustained complement inhibition over extended periods without frequent re-dosing
Solution Approach 2:
The invention transitions from short-acting compstatin that requires frequent administration to long-acting analogs that function as sustained-release therapeutic agents, effectively replacing the need for repeated dosing with a single or reduced-frequency administration regimen
2Reliability
If frequent dosing is administered to maintain complement inhibition, then therapeutic effect can be sustained, but side effects increase due to frequent administration
Solution Approach 1:
By changing the pharmacokinetic parameters of the therapeutic agent through structural modification of compstatin analogs, the patent achieves sustained therapeutic effects at lower administration frequencies, thereby reducing cumulative side effects associated with frequent dosing while maintaining reliable complement inhibition
3Loss of time
If long-acting compstatin analogs are developed, then dosing frequency can be reduced, but formulation and administration complexity increases
Solution Approach 1:
The patent employs parameter changes in the molecular structure of compstatin analogs to inherently achieve long-acting properties, avoiding the need for complex delivery systems or formulations. The structural modifications themselves provide the extended duration of action, simplifying the overall administration approach despite the chemical complexity of the analogs
Data Source
AI summary
In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.